Advanced

Thymidylate synthase : A predictive biomarker in resected colorectal liver metastases receiving 5-FU treatment

Torén, William; Ansari, Daniel LU ; Andersson, Bodil LU ; Spelt, Lidewij LU and Andersson, Roland LU (2018) In Future Oncology 14(4). p.343-351
Abstract

Aim: To investigate the role of thymidylate synthase (TS) as a predictive biomarker in patients with resected colorectal liver metastases (CRLM). Materials & methods: PubMed, EMBASE and Cochrane Library were queried up to June 2017. Meta-analysis was performed using random-effects model. Risk of bias was assessed using funnel plots. Results: Six eligible studies were included, comprising a total of 542 patients. Meta-analysis demonstrated a trend to reduced overall survival in patients with resected CRLM with TS overexpression, with a hazard ratio of 1.13 (95% CI: 0.99-1.29; p = 0.08). In three studies where patients received systemic fluorouracil, the pooled hazard ratio was 2.25 (95% CI: 1.37-3.71; p = 0.001). Conclusion: TS... (More)

Aim: To investigate the role of thymidylate synthase (TS) as a predictive biomarker in patients with resected colorectal liver metastases (CRLM). Materials & methods: PubMed, EMBASE and Cochrane Library were queried up to June 2017. Meta-analysis was performed using random-effects model. Risk of bias was assessed using funnel plots. Results: Six eligible studies were included, comprising a total of 542 patients. Meta-analysis demonstrated a trend to reduced overall survival in patients with resected CRLM with TS overexpression, with a hazard ratio of 1.13 (95% CI: 0.99-1.29; p = 0.08). In three studies where patients received systemic fluorouracil, the pooled hazard ratio was 2.25 (95% CI: 1.37-3.71; p = 0.001). Conclusion: TS appears to be a clinically relevant predictive biomarker in patients with resected CRLM receiving systemic 5-FU.

(Less)
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
biomarker, colorectal liver metastases, predictive, prognosis, thymidylate synthase
in
Future Oncology
volume
14
issue
4
pages
9 pages
publisher
Future Medicine Ltd.
external identifiers
  • scopus:85041331404
ISSN
1479-6694
DOI
10.2217/fon-2017-0431
language
English
LU publication?
yes
id
6922c5c4-90b7-44d6-9923-0b88bed8a07d
date added to LUP
2018-03-06 12:41:25
date last changed
2018-05-29 10:44:00
@article{6922c5c4-90b7-44d6-9923-0b88bed8a07d,
  abstract     = {<p>Aim: To investigate the role of thymidylate synthase (TS) as a predictive biomarker in patients with resected colorectal liver metastases (CRLM). Materials &amp; methods: PubMed, EMBASE and Cochrane Library were queried up to June 2017. Meta-analysis was performed using random-effects model. Risk of bias was assessed using funnel plots. Results: Six eligible studies were included, comprising a total of 542 patients. Meta-analysis demonstrated a trend to reduced overall survival in patients with resected CRLM with TS overexpression, with a hazard ratio of 1.13 (95% CI: 0.99-1.29; p = 0.08). In three studies where patients received systemic fluorouracil, the pooled hazard ratio was 2.25 (95% CI: 1.37-3.71; p = 0.001). Conclusion: TS appears to be a clinically relevant predictive biomarker in patients with resected CRLM receiving systemic 5-FU.</p>},
  author       = {Torén, William and Ansari, Daniel and Andersson, Bodil and Spelt, Lidewij and Andersson, Roland},
  issn         = {1479-6694},
  keyword      = {biomarker,colorectal liver metastases,predictive,prognosis,thymidylate synthase},
  language     = {eng},
  month        = {02},
  number       = {4},
  pages        = {343--351},
  publisher    = {Future Medicine Ltd.},
  series       = {Future Oncology},
  title        = {Thymidylate synthase : A predictive biomarker in resected colorectal liver metastases receiving 5-FU treatment},
  url          = {http://dx.doi.org/10.2217/fon-2017-0431},
  volume       = {14},
  year         = {2018},
}